216 related articles for article (PubMed ID: 36055381)
1. Development of a biomarker to monitor target engagement after treatment with dihydroorotate dehydrogenase inhibitors.
Pontikos MA; Leija C; Zhao Z; Wang X; Kilgore J; Tornesi B; Adenmatten N; Phillips MA; Williams NS
Biochem Pharmacol; 2022 Oct; 204():115237. PubMed ID: 36055381
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of dihydroorotate dehydrogenase (DHODH) inhibitors "leflunomide" and "teriflunomide" in Covid-19: A narrative review.
Kaur H; Sarma P; Bhattacharyya A; Sharma S; Chhimpa N; Prajapat M; Prakash A; Kumar S; Singh A; Singh R; Avti P; Thota P; Medhi B
Eur J Pharmacol; 2021 Sep; 906():174233. PubMed ID: 34111397
[TBL] [Abstract][Full Text] [Related]
3. A long-duration dihydroorotate dehydrogenase inhibitor (DSM265) for prevention and treatment of malaria.
Phillips MA; Lotharius J; Marsh K; White J; Dayan A; White KL; Njoroge JW; El Mazouni F; Lao Y; Kokkonda S; Tomchick DR; Deng X; Laird T; Bhatia SN; March S; Ng CL; Fidock DA; Wittlin S; Lafuente-Monasterio M; Benito FJ; Alonso LM; Martinez MS; Jimenez-Diaz MB; Bazaga SF; Angulo-Barturen I; Haselden JN; Louttit J; Cui Y; Sridhar A; Zeeman AM; Kocken C; Sauerwein R; Dechering K; Avery VM; Duffy S; Delves M; Sinden R; Ruecker A; Wickham KS; Rochford R; Gahagen J; Iyer L; Riccio E; Mirsalis J; Bathhurst I; Rueckle T; Ding X; Campo B; Leroy D; Rogers MJ; Rathod PK; Burrows JN; Charman SA
Sci Transl Med; 2015 Jul; 7(296):296ra111. PubMed ID: 26180101
[TBL] [Abstract][Full Text] [Related]
4. Effect of the Intramolecular Hydrogen Bond on the Active Metabolite Analogs of Leflunomide for Blocking the Plasmodium falciparum Dihydroorotate Dehydrogenase Enzyme: QTAIM, NBO, and Docking Study.
Heidarian R; Zahedi-Tabrizi M
Curr Comput Aided Drug Des; 2021; 17(3):480-491. PubMed ID: 32459610
[TBL] [Abstract][Full Text] [Related]
5. Antimalarial activity of single-dose DSM265, a novel plasmodium dihydroorotate dehydrogenase inhibitor, in patients with uncomplicated Plasmodium falciparum or Plasmodium vivax malaria infection: a proof-of-concept, open-label, phase 2a study.
Llanos-Cuentas A; Casapia M; Chuquiyauri R; Hinojosa JC; Kerr N; Rosario M; Toovey S; Arch RH; Phillips MA; Rozenberg FD; Bath J; Ng CL; Cowell AN; Winzeler EA; Fidock DA; Baker M; Möhrle JJ; Hooft van Huijsduijnen R; Gobeau N; Araeipour N; Andenmatten N; Rückle T; Duparc S
Lancet Infect Dis; 2018 Aug; 18(8):874-883. PubMed ID: 29909069
[TBL] [Abstract][Full Text] [Related]
6. Identification and Mechanistic Understanding of Dihydroorotate Dehydrogenase Point Mutations in Plasmodium falciparum that Confer in Vitro Resistance to the Clinical Candidate DSM265.
White J; Dhingra SK; Deng X; El Mazouni F; Lee MCS; Afanador GA; Lawong A; Tomchick DR; Ng CL; Bath J; Rathod PK; Fidock DA; Phillips MA
ACS Infect Dis; 2019 Jan; 5(1):90-101. PubMed ID: 30375858
[TBL] [Abstract][Full Text] [Related]
7. Precision Medicine With Leflunomide: Consideration of the DHODH Haplotype and Plasma Teriflunomide Concentration and Modification of Outcomes in Patients With Rheumatoid Arthritis.
Wiese MD; Hopkins AM; King C; Wechalekar MD; Lee A; Spargo L; Metcalf R; McWilliams L; Hill C; Cleland LG; Proudman SM
Arthritis Care Res (Hoboken); 2021 Jul; 73(7):983-989. PubMed ID: 32339392
[TBL] [Abstract][Full Text] [Related]
8. Diverse evolutionary pathways challenge the use of collateral sensitivity as a strategy to suppress resistance.
Mandt REK; Luth MR; Tye MA; Mazitschek R; Ottilie S; Winzeler EA; Lafuente-Monasterio MJ; Gamo FJ; Wirth DF; Lukens AK
Elife; 2023 Sep; 12():. PubMed ID: 37737220
[TBL] [Abstract][Full Text] [Related]
9. A Triazolopyrimidine-Based Dihydroorotate Dehydrogenase Inhibitor with Improved Drug-like Properties for Treatment and Prevention of Malaria.
Phillips MA; White KL; Kokkonda S; Deng X; White J; El Mazouni F; Marsh K; Tomchick DR; Manjalanagara K; Rudra KR; Wirjanata G; Noviyanti R; Price RN; Marfurt J; Shackleford DM; Chiu FC; Campbell M; Jimenez-Diaz MB; Bazaga SF; Angulo-Barturen I; Martinez MS; Lafuente-Monasterio M; Kaminsky W; Silue K; Zeeman AM; Kocken C; Leroy D; Blasco B; Rossignol E; Rueckle T; Matthews D; Burrows JN; Waterson D; Palmer MJ; Rathod PK; Charman SA
ACS Infect Dis; 2016 Dec; 2(12):945-957. PubMed ID: 27641613
[TBL] [Abstract][Full Text] [Related]
10. Lead Optimization of a Pyrrole-Based Dihydroorotate Dehydrogenase Inhibitor Series for the Treatment of Malaria.
Kokkonda S; Deng X; White KL; El Mazouni F; White J; Shackleford DM; Katneni K; Chiu FCK; Barker H; McLaren J; Crighton E; Chen G; Angulo-Barturen I; Jimenez-Diaz MB; Ferrer S; Huertas-Valentin L; Martinez-Martinez MS; Lafuente-Monasterio MJ; Chittimalla R; Shahi SP; Wittlin S; Waterson D; Burrows JN; Matthews D; Tomchick D; Rathod PK; Palmer MJ; Charman SA; Phillips MA
J Med Chem; 2020 May; 63(9):4929-4956. PubMed ID: 32248693
[TBL] [Abstract][Full Text] [Related]
11. Investigating dihydroorotate dehydrogenase inhibitor mediated mitochondrial dysfunction in hepatic in vitro models.
Jones SW; Penman SL; French NS; Park BK; Chadwick AE
Toxicol In Vitro; 2021 Apr; 72():105096. PubMed ID: 33460737
[TBL] [Abstract][Full Text] [Related]
12. In vitro selection predicts malaria parasite resistance to dihydroorotate dehydrogenase inhibitors in a mouse infection model.
Mandt REK; Lafuente-Monasterio MJ; Sakata-Kato T; Luth MR; Segura D; Pablos-Tanarro A; Viera S; Magan N; Ottilie S; Winzeler EA; Lukens AK; Gamo FJ; Wirth DF
Sci Transl Med; 2019 Dec; 11(521):. PubMed ID: 31801884
[TBL] [Abstract][Full Text] [Related]
13. Dihydroorotate dehydrogenase inhibitors in anti-infective drug research.
Boschi D; Pippione AC; Sainas S; Lolli ML
Eur J Med Chem; 2019 Dec; 183():111681. PubMed ID: 31557612
[TBL] [Abstract][Full Text] [Related]
14. Recent developments in the medicinal chemistry and therapeutic potential of dihydroorotate dehydrogenase (DHODH) inhibitors.
Vyas VK; Ghate M
Mini Rev Med Chem; 2011 Oct; 11(12):1039-55. PubMed ID: 21861807
[TBL] [Abstract][Full Text] [Related]
15. Tetrahydro-2-naphthyl and 2-Indanyl Triazolopyrimidines Targeting Plasmodium falciparum Dihydroorotate Dehydrogenase Display Potent and Selective Antimalarial Activity.
Kokkonda S; Deng X; White KL; Coteron JM; Marco M; de Las Heras L; White J; El Mazouni F; Tomchick DR; Manjalanagara K; Rudra KR; Chen G; Morizzi J; Ryan E; Kaminsky W; Leroy D; Martínez-Martínez MS; Jimenez-Diaz MB; Bazaga SF; Angulo-Barturen I; Waterson D; Burrows JN; Matthews D; Charman SA; Phillips MA; Rathod PK
J Med Chem; 2016 Jun; 59(11):5416-31. PubMed ID: 27127993
[TBL] [Abstract][Full Text] [Related]
16. Potent Antimalarials with Development Potential Identified by Structure-Guided Computational Optimization of a Pyrrole-Based Dihydroorotate Dehydrogenase Inhibitor Series.
Palmer MJ; Deng X; Watts S; Krilov G; Gerasyuto A; Kokkonda S; El Mazouni F; White J; White KL; Striepen J; Bath J; Schindler KA; Yeo T; Shackleford DM; Mok S; Deni I; Lawong A; Huang A; Chen G; Wang W; Jayaseelan J; Katneni K; Patil R; Saunders J; Shahi SP; Chittimalla R; Angulo-Barturen I; Jiménez-Díaz MB; Wittlin S; Tumwebaze PK; Rosenthal PJ; Cooper RA; Aguiar ACC; Guido RVC; Pereira DB; Mittal N; Winzeler EA; Tomchick DR; Laleu B; Burrows JN; Rathod PK; Fidock DA; Charman SA; Phillips MA
J Med Chem; 2021 May; 64(9):6085-6136. PubMed ID: 33876936
[TBL] [Abstract][Full Text] [Related]
17. Identification of 3,4-Dihydro-2
Hartuti ED; Sakura T; Tagod MSO; Yoshida E; Wang X; Mochizuki K; Acharjee R; Matsuo Y; Tokumasu F; Mori M; Waluyo D; Shiomi K; Nozaki T; Hamano S; Shiba T; Kita K; Inaoka DK
Int J Mol Sci; 2021 Jul; 22(13):. PubMed ID: 34281290
[No Abstract] [Full Text] [Related]
18. Malarial dihydroorotate dehydrogenase. Substrate and inhibitor specificity.
Baldwin J; Farajallah AM; Malmquist NA; Rathod PK; Phillips MA
J Biol Chem; 2002 Nov; 277(44):41827-34. PubMed ID: 12189151
[TBL] [Abstract][Full Text] [Related]
19. A novel series of teriflunomide derivatives as orally active inhibitors of human dihydroorotate dehydrogenase for the treatment of colorectal carcinoma.
Li C; Zhou Y; Xu J; Zhou X; Huang Z; Zeng T; Yang X; Tao L; Gou K; Zhong X; Chen Q; Luo Y; Zhao Y
Eur J Med Chem; 2022 Aug; 238():114489. PubMed ID: 35640328
[TBL] [Abstract][Full Text] [Related]
20. Recent advances on patents of
Gehlot P; Vyas VK
Expert Opin Ther Pat; 2023; 33(9):579-596. PubMed ID: 37942637
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
